Get started
INTRON BIOTECHNOLOGY, INC.INTRON BIOTECHNOLOGY, INC.INTRON BIOTECHNOLOGY, INC.

INTRON BIOTECHNOLOGY, INC.

No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

048530 fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

iNtRON Biotechnology, Inc. engages in the development of new biopharmaceuticals, alternatives to antibiotics for animals, and molecular diagnosis. It operates through the New Testament Part and DR Part business divisions. The New Testament Part business division is involved in technology transfer revenue, services, and royalties, antibiotic alternatives. The DR Part business division refers to COVID-19, AI, VRE, and STI. The company was founded on January 18, 1999 and is headquartered in Seongnam-si, South Korea.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
048530 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company